| pubmed-article:20471253 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20471253 | lifeskim:mentions | umls-concept:C0034326 | lld:lifeskim |
| pubmed-article:20471253 | lifeskim:mentions | umls-concept:C0389995 | lld:lifeskim |
| pubmed-article:20471253 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:20471253 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:20471253 | pubmed:dateCreated | 2010-6-4 | lld:pubmed |
| pubmed-article:20471253 | pubmed:abstractText | The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2. | lld:pubmed |
| pubmed-article:20471253 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20471253 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20471253 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20471253 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20471253 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20471253 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20471253 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20471253 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20471253 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20471253 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:LiXiangX | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:HickeyEugene... | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:BosanacToddT | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:KashemMohamme... | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:SchlyerSabine... | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:YoungErick... | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:OlagueAlanA | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:GinnJohnJ | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:KerrStevenS | lld:pubmed |
| pubmed-article:20471253 | pubmed:author | pubmed-author:KuglerStanley... | lld:pubmed |
| pubmed-article:20471253 | pubmed:copyrightInfo | Copyright 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20471253 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20471253 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20471253 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20471253 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20471253 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20471253 | pubmed:pagination | 3746-9 | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:meshHeading | pubmed-meshheading:20471253... | lld:pubmed |
| pubmed-article:20471253 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20471253 | pubmed:articleTitle | Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. | lld:pubmed |
| pubmed-article:20471253 | pubmed:affiliation | Department of Medicinal Chemistry, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. todd.bosanac@boehringer-ingelheim.com | lld:pubmed |
| pubmed-article:20471253 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20471253 | lld:chembl |
